Literature DB >> 25771509

Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset.

Birgitte Rahbek Kornum1, Fabio Pizza2, Stine Knudsen3, Giuseppe Plazzi2, Poul Jennum4, Emmanuel Mignot5.   

Abstract

Type 1 narcolepsy is caused by a loss of hypocretin (orexin) signaling in the brain. Genetic data suggests the disorder is caused by an autoimmune attack on hypocretin producing neurons in hypothalamus. This hypothesis has however not yet been confirmed by consistent findings of autoreactive antibodies or T-cells in patient samples. One explanation for these negative results may be that the autoimmune process is no longer active when patients present to the clinic. With increasing awareness in recent years, more and more patients have been diagnosed closer and closer to disease onset. In this study, we tested whether an active immune process in the brain could be detected in these patients, as reflected by increased cytokine levels in the cerebrospinal fluid (CSF). Using multiplex analysis, we measured the levels of 51 cytokines and chemokines in the CSF of 40 type 1 narcolepsy patients having varying disease duration. For comparison, we used samples from 9 healthy controls and 9 patients with other central hypersomnia. Cytokine levels did not differ significantly between controls and patients, even in 5 patients with disease onset less than a month prior to CSF sampling.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Cataplexy; Cerebrospinal fluid; Chemokines; Cytokines; Hypocretin; Narcolepsy

Mesh:

Substances:

Year:  2015        PMID: 25771509      PMCID: PMC4567452          DOI: 10.1016/j.bbi.2015.03.004

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  21 in total

1.  Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling.

Authors:  Ferdousi Chowdhury; Anthony Williams; Peter Johnson
Journal:  J Immunol Methods       Date:  2008-11-05       Impact factor: 2.303

2.  CSF immune variables in patients with narcolepsy.

Authors:  S Fredrikson; B Carlander; M Billiard; H Link
Journal:  Acta Neurol Scand       Date:  1990-03       Impact factor: 3.209

3.  Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation.

Authors:  M Cristina Lebre; Tim Burwell; Pedro L Vieira; Jose Lora; Anthony J Coyle; Martien L Kapsenberg; Björn E Clausen; Esther C De Jong
Journal:  Immunol Cell Biol       Date:  2005-10       Impact factor: 5.126

Review 4.  Th1 and Th17 cells: adversaries and collaborators.

Authors:  Jesse M Damsker; Anna M Hansen; Rachel R Caspi
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

5.  Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis.

Authors:  D Maimone; S Gregory; B G Arnason; A T Reder
Journal:  J Neuroimmunol       Date:  1991-04       Impact factor: 3.478

6.  Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.

Authors:  J Mellergård; M Edström; M Vrethem; J Ernerudh; C Dahle
Journal:  Mult Scler       Date:  2009-12-09       Impact factor: 6.312

Review 7.  CSF hypocretin-1 assessment in sleep and neurological disorders.

Authors:  Patrice Bourgin; Jamie M Zeitzer; Emmanuel Mignot
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182

8.  HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines.

Authors:  F A Ennis; A H Rook; Y H Qi; G C Schild; D Riley; R Pratt; C W Potter
Journal:  Lancet       Date:  1981-10-24       Impact factor: 79.321

9.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies.

Authors:  Fabrice Carrat; Elisabeta Vergu; Neil M Ferguson; Magali Lemaitre; Simon Cauchemez; Steve Leach; Alain-Jacques Valleron
Journal:  Am J Epidemiol       Date:  2008-01-29       Impact factor: 4.897

10.  IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

Authors:  Mark A Kroenke; Thaddeus J Carlson; Anuska V Andjelkovic; Benjamin M Segal
Journal:  J Exp Med       Date:  2008-06-23       Impact factor: 14.307

View more
  11 in total

Review 1.  Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Authors:  Lucie Barateau; Roland Liblau; Christelle Peyron; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 2.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

3.  CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice.

Authors:  Raphaël Bernard-Valnet; Lidia Yshii; Clémence Quériault; Xuan-Hung Nguyen; Sébastien Arthaud; Magda Rodrigues; Astrid Canivet; Anne-Laure Morel; Arthur Matthys; Jan Bauer; Béatrice Pignolet; Yves Dauvilliers; Christelle Peyron; Roland S Liblau
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

4.  Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time.

Authors:  Claudio Liguori; Fabio Placidi; Francesca Izzi; Marzia Nuccetelli; Sergio Bernardini; Maria Giovanna Sarpa; Fabrizio Cum; Maria Grazia Marciani; Nicola Biagio Mercuri; Andrea Romigi
Journal:  Sleep Breath       Date:  2016-01-23       Impact factor: 2.816

Review 5.  Autoimmunity in narcolepsy.

Authors:  Melodie Bonvalet; Hanna M Ollila; Aditya Ambati; Emmanuel Mignot
Journal:  Curr Opin Pulm Med       Date:  2017-11       Impact factor: 3.155

6.  Narcolepsy susceptibility gene CCR3 modulates sleep-wake patterns in mice.

Authors:  Hiromi Toyoda; Yoshiko Honda; Susumu Tanaka; Taku Miyagawa; Makoto Honda; Kazuki Honda; Katsushi Tokunaga; Tohru Kodama
Journal:  PLoS One       Date:  2017-11-29       Impact factor: 3.240

7.  CD4+ T-Cell Reactivity to Orexin/Hypocretin in Patients With Narcolepsy Type 1.

Authors:  Melanie Ramberger; Birgit Högl; Ambra Stefani; Thomas Mitterling; Markus Reindl; Andreas Lutterotti
Journal:  Sleep       Date:  2017-03-01       Impact factor: 5.849

8.  Histamine in murine narcolepsy: What do genetic and immune models tell us?

Authors:  Silvia Melzi; Anne-Laure Morel; Céline Scoté-Blachon; Roland Liblau; Yves Dauvilliers; Christelle Peyron
Journal:  Brain Pathol       Date:  2021-10-21       Impact factor: 6.508

9.  High-dimensional single-cell analysis reveals the immune signature of narcolepsy.

Authors:  Felix J Hartmann; Raphaël Bernard-Valnet; Clémence Quériault; Dunja Mrdjen; Lukas M Weber; Edoardo Galli; Carsten Krieg; Mark D Robinson; Xuan-Hung Nguyen; Yves Dauvilliers; Roland S Liblau; Burkhard Becher
Journal:  J Exp Med       Date:  2016-11-07       Impact factor: 14.307

Review 10.  COVID-19: dealing with a potential risk factor for chronic neurological disorders.

Authors:  Tommaso Schirinzi; Doriana Landi; Claudio Liguori
Journal:  J Neurol       Date:  2020-08-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.